The absence of C-suite selling and the modest dollar amount limit the bearish signal, but the cluster of two directors selling without a 10b5-1 plan suggests potential caution ahead of upcoming data readouts or regulatory events. Monitor for any Form 4 filings from officers or additional director sales in the next 30 days.
Price Chart
Executive Summary
Two directors at Puma Biotechnology sold a combined $612K in open-market shares over a one-week window, with the bulk ($567K) sold by Director Cesano Alessandra following a derivative exercise. The sales represent ~0.19% of the company's $326M market cap — a modest but notable insider cluster. No C-suite officers participated, and the sales lack a clear 10b5-1 pattern, suggesting potential caution ahead of upcoming events.
Key Financial Metrics
Key Facts
- Two directors sold a total of ~67K shares for $612K in open-market transactions from Sep 7-14, 2026.
- Director Cesano Alessandra sold 62,150 shares at $9.12 after exercising 50,000 options at $2.93 (net economic sale of ~$420K after exercise cost).
- Director Troy Edward Wilson sold 5,000 shares at $9.10 for $46K.
- No C-suite officers (CEO, CFO, etc.) participated in the selling; no insider purchases were recorded.
- Total sales represent ~0.19% of the company's $326M market cap — modest but above the trivial threshold.
- No 10b5-1 plan indication was noted for either sale, reducing the likelihood of routine liquidity-driven selling.
Financial Impact
Insider sales of $612K represent ~0.19% of market cap — modest but notable for a biotech with no recent major catalyst.
Risk Factors
- Further insider selling could signal deteriorating confidence in pipeline or commercial prospects.
- No insider buying to offset the selling — lack of conviction from board members.
- Biotech sector volatility could amplify any negative read-through from insider activity.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PBYI-1789607657729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13D/A | $9.81 | awaiting T+20 | — | $10.94 (+11.47%) |
Sep 16, 2026 5w ago | Insider Cluster | $9.52 $10.52 | ▼ −10.50% | ▼ −9.30% | $10.94 (−14.86%) |
Jul 8, 2026 15w ago | Insider Cluster | $7.90 $8.12 | ▲ +2.78% | ▲ +0.54% | $10.94 (+38.42%) |
Jul 6, 2026 16w ago | 144 | $7.96 $7.69 | ▼ −3.39% | ▼ −4.72% | $10.94 (+37.37%) |
Jun 15, 2026 19w ago | Insider Cluster | $7.17 $8.28 | ▲ +15.48% | ▲ +15.28% | $10.94 (+52.51%) |
Jun 12, 2026 19w ago | 144 | $7.33 $8.00 | ▲ +9.14% | ▲ +7.36% | $10.94 (+49.18%) |
Feb 26, 2026 34w ago | 8-K | $5.70 $6.08 | ▲ +6.67% | ▲ +14.22% | $10.94 (+91.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers